Recently, LPA receptors have been considered to be interesting targets for the development of new drugs in view of efforts to evaluate the clinical efficacies of LPA1 and LPA1/3 antagonists in tissue fibrosis (ClinicalTrials.gov ID: NCT01766817), psoriasis (ClinicalTrials.gov ID: NCT02763969), and systemic sclerosis (ClinicalTrials.gov ID: NCT01651143). This evidence concerns the gene LPAR1 and systemic sclerosis.